Lymphoma. Anas Younes, MD Professor of Medicine The University of Texas M. D. Anderson Cancer Center Houston, TX
|
|
- Archibald Carson
- 6 years ago
- Views:
Transcription
1 Best of ASCO 2011 Lymphoma Anas Younes, MD Professor of Medicine The University of Texas M. D. Anderson Cancer Center Houston, TX RCHOP21 in DLBCL (GELA LNH-98.5 Study) Survival Probability OS (N = 399) 1 CHOP R-CHOP P = Yrs Coiffier B, et al. NEJM 2002, updated ASCO Abstract
2 Current Regimens in Lymphoma: Recycling Old Drugs Disease Frontline Regimen Salvage Regimen DLBCL RCHOP R-ICE R-ESHAP R-DHAP T-Cell NHL CHOP ICE ESHAP DHAP MCL RCHOP R-Hyper-CVAD chl ABVD ICE ESHAP DHAP GND, IGEV CHOP RCHOP RCHOP ABVD ABVD ABVD Early 1970s ABVD=doxorubicin, bleomycin, vinblastine, and dacarbazine; chl=classical Hodgkin lymphoma; DLBCL=diffuse large B-cell lymphoma; GND= gemcitabine, vinorelbine, and liposomal doxorubicin; IGEV=ifosfamide, gemcitabine, and vinorelbine; MCL=mantle cell lymphoma; NHL=non-Hodgkin lymphoma; R-CHOP=rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R- DHAP=rituximab, dexamethasone, ara-c, and cisplatin; R-ESHAP=rituximab, etoposide, cytarabine, cisplatin, and prednisone; R- Hyper-CVAD=rituximab, hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone; R-ICE=rituximab, ifosfamide, carboplatin, and etoposide. How To Improve The Cure of Diffuse Large Cell Lymphoma? Improve the efficacy of front line regimens Should we intensify RCHOP21-based therapy? is R-CHOP14 better than R- CHOP21? Is RCHOP + ASCT better than RCHOP Should we add new agents to RCHOP21 Small molecules : Enzastaurin, Bortezomib, Lenalidomide Antibodies: Epratuzomab Emerging new agents Improve the efficacy of salvage therapy What is the best salvage regimen in the rituximab era Should we add new agents to salvage regimens 2
3 A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of newly diagnosed diffuse large B cell lymphoma Results from a trial by the UK NCRI Lymphoma Clinical Study Group (CRUKE/03/019) D. Cunningham, P. Smith, P. Mouncey, W. Qian, C. Pocock, K. M. Ardeshna, J. Radford, J. Davies, A. McMillan, D. Linch on behalf of the NCRI trial collaborators Trial design: R-CHOP14 vs. 21 Newly diagnosed CD20+ve DLBCL Stratified by IPI (0-1, 2, 3, 4-5) Age 60 vs. >60 Treatment centre R n=540 n=540 R-CHOP21 CHOP21 8 cycles Rituximab 8cycles R-CHOP14 CHOP14 6 cycles Rituximab 8 cycles Lenograstim Day patients; 119 sites Recruitment March Nov
4 Overall response rates Based on end of treatment scan R-CHOP21 % R-CHOP14 % CR CRu PR SD 6 5 PD/relapse 6 4 CR/CRu, p= CR/CRu/PR, p= RCHOP21 vs RCHOP14 PFS OS R- R CHOP21 CHOP Events R- 123 (23) 117 (22) 0.5 R-CHOP21 CHOP14 0.5, n 2-yr (%) 81% 83% Logrank OS p=0.70 Events, n (29) 153 (28) 0. (%) 4 HR test yr FFS 75% 75% 0.3 (95% 0.95 ( ) Log-rank p=0.94 CI) 0.2 HR test 0.2 (95% R-CHOP ( ) CI) R-CHOP21 R-CHOP21 R-CHOP Patients at Risk Years from randomisation Patients at Risk Years from randomisation R-CHOP R-CHOP R-CHOP R-CHOP Probability Probability 4
5 Conclusions In patients receiving Rituximab, CHOP14 for 6 cycles is not superior to CHOP21 for 8 cycles No obvious sub group appears to derive a greater benefit from R-CHOP14, including age > 60, high IPI, high MIB1 or non-gc phenotype As expected a higher frequency of neutropenia was observed in R-CHOP21 which h reflects the primary prophylaxis with G-CSF in R-CHOP14 Randomized phase III US / Canadian Intergroup trial (SWOG S9704) comparing CHOP±R x 8 vs CHOP±R x 6 followed by high dose therapy and auto transplant for patients with diffuse aggressive non-hodgkin s lymphoma (NHL) in high- intermediate (H-Int) or high IPI risk groups. P.J. Stiff 1, J.M. Unger 2 J.R. Cook 3, L.S. Constine 4, S. Couban 5, T.C. Shea 6, J.N. Winter 7, T.P. Miller 8, R.R. Tubbs 3, D.C. Marcellus 9, J. Friedberg 4, K. Barton 1, G. Mills 10, M. LeBlanc 2, L. Rimsza 8, S.J. Forman 11, R.I. Fisher 4 1 Loyola University Medical Center, Maywood, IL; 2 SWOG Statistical Center, Seattle, WA; 3 Cleveland Clinic Foundation, Cleveland, OH; 4 University of Rochester, Rochester, NY; 5 Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, CAN; 6 University of North Carolina at Chapel Hill, Chapel Hill, NC; 7 Northwestern University, Chicago, IL; 8 University of Arizona, Tucson, AZ; 9 Margaret and Charles Juravinski Cancer Centre, Hamilton, Ontario, CAN; 10 Louisiana State University Medical Center, Shreveport, LA; 11 City of Hope Medical Center, Duarte, CA 5
6 Schema CHOP or CHOP-R x 5 PR or CR <PR CHOP/CHOP-R x 1 CHOP/CHOP-R x 3 + Auto transplant Randomized phase III US / Canadian Intergroup trial (SWOG S9704) comparing CHOP±R x 8 vs CHOP±R x 6 followed by high dose therapy and auto transplant for patients with diffuse aggressive non-hodgkin s lymphoma (NHL) in high-intermediate (H-Int) or high IPI risk groups. 6
7 Targeted Therapy for Lymphoma Treatment Younes A. (2010) Beyond chemotherapy: new agents for targeted treatment of lymphoma. Nat Rev Clin Oncol. doi: /nrclinonc Single-Agent Activity in Relapsed DLBCL Overall Response Rate Everolimus SAR3419 Temsirolimus Lenalidomide MGCD0103 Fostambinib PCI32765 CMC544 Epratuzumab SGN40 Vorinostat YM155 ABT236 Mapatumumab 35% 33% 32% 28% 24% 22% 17% 15% 10% 10% 5% 3% 0% 0% 0% 20% 40% 60% 80% 100% Younes A. (2010) Beyond chemotherapy: new agents for targeted treatment of lymphoma. Nat Rev Clin Oncol. doi: /nrclinonc
8 Lenalidomide An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-hodgkin lymphoma % Response Rate in Different Histologies DLBCL FL MCL SLL/CLL T-Cell HL Relapsed NHL Rituximab 30% 50% 30% 15% - - Lenalidomide 28% 27% 42% 22% 45% 18% Witzig T E et al. Ann Oncol. 2011;annonc.mdq62.6 CLL=chronic lymphocytic leukemia; HL=Hodgkin lymphoma; SLL=small lymphocytic leukemia. A Phase II/III Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide vs Investigator's Choice in Patients With Relapsed or Refractory DLBCL Experimental Drug: lenalidomide Lenalidomide 25 mg p.o. for 21/28 days until progressive disease. For pts with creatinine clearance 30 ml/min but <60 ml/min, lenalidomide 10 mg (max escalation is 15 mg). Investigator's Choice: active comparator with one of the following Lenalidomide de Gemcitabine 1250 mg/m2 IV days 1, 8, and 15/28 d for 6 cycles Oxaliplatin 100 mg/m2 IV day 1/21 d for 6 cycles Rituximab 375 mg/m2 IV days 1, 8, 15, and 22 cycle 1, and if SD at wk 12, also on day 1 of cycles 4, 6, 8, and 10 (CD20+ pts only) Etoposide 100 mg/m2 IV days 1-5/28 d for 6 cycles OR 50 mg/m2 oral days 1-21/28 d for 6 cycles 8
9 Combination Strategies With Conventional Regimens Randomized Phase III Trials in DLBCL Frontline - RCHOP ± enzastaurin - RCHOP ± everolimus - RCHOP ± lenalidomide RCHOP ± epratuzumab RCHOP ± bortezomib Pretransplant RICE ± X Posttransplant & not eligible for SCT CORAL: COllaborative trial in Relapsed Aggressive Lymphoma Maintenance with rituximab after autologous stem cell transplantation (ASCT) in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL): CORAL final analysis C. Gisselbrecht, B. Glass, G. Laurent, D. S. Gill, M. D. Linch, M. Trneny, D. Bron, O. Shpilberg, H. Hagberg, M. Bargetzi, D. Ma, J. Briere, C. Moskowitz, N. Schmitz 9
10 CORAL trial: Study design Relapsed/ refractory DLBCL n = 396 R A N D O M I S E R-ICE x 3 R-DHAP x 3 Which salvage regimen is the best? PR, CR SD, PD R-DHAP = rituximab, dexamethasone, off study high-dose cytarabine, cisplatin ASCT BEAM R-ICE = rituximab, ifosfamide, carboplatin, etoposide R A N D O M I S E Rituximab 375 mg/m 2 q2mo x 6 Observation only Place of immunotherapy Post-transplantation? Gisselbrecht C, et al. J Clin Oncol 2010; 28: CORAL by induction treatment robability Survival p EFS (induction ITT) 1.0 R-ICE R-DHAP Survival p robability OS (induction ITT) R-ICE R-DHAP 0.0 p = p = EFS (months) OS (months) 10
11 CORAL by maintenance Survival probability PFS OS Observation Rituximab p = p = Survival probability 1.0 Observation 0.8 Rituximab PFS (months) Overall survival (months) Combination Strategies With Conventional Regimens Randomized Phase III Trials in DLBCL Frontline - RCHOP ± enzastaurin - RCHOP ± everolimus - RCHOP ± lenalidomide RCHOP ± epratuzumab RCHOP ± bortezomib Pretransplant RICE ± X Posttransplant & not eligible for SCT 11
12 The Challenge of Hodgkin Lymphoma Hodgkin Lymphoma by Era (N = 2167) Disease-Specific Survival Overall Survival Courtesy of Joe Connors, personal communication Relapse After ASCT: OS by Era of Transplant Overall Survival <1990 median 1.9 yrs median 2.6 yrs >2000* median 1.9 yrs >2000 vs : P (Gehan) =.02, P (logrank) =.03 Horning S et al, 2008 Lugano Hodgkin s Lymphoma Presentation 12
13 Current Regimens in HL Lymphoma Disease Front-Line Regimen Salvage Regimen chl ABVD ICE ESHAP DHAP GND, IGEV CHOP ABVD RCHOP ABVD RCHOP ABVD Early 1970s Single-Agent Activity in Relapsed chl Agent Target Route Phase N PR CR PR + CR 1 st Author SGN30 CD30 IV I/II (0%) Bartlett MDX060 CD30 IV II (8%) Ansell SGN35 CD30 IV I ( 3 wks) (37%) Younes SGN35 CD30 IV I (weekly) (46%) Fanale SGN35 CD30 IV II (3 wks) (74) 75% Chen MGCD0103 HDACs Oral II (38%) Younes Panobinostat HDACs Oral I (40%) DeAngelo Panobinostat HDACs Oral II (27%) Sureda Vorinostat HDACs Oral II (4%) Kirshbaum Lenalidomide? Oral II (17%) Fehniger Lenalidomide? Oral II (13%) Kuruvilla Everolimus mtor Oral II (53%) Johnston Younes A. Hematology Am Soc Hematol Educ Program. 2009: Younes A, et al. N Engl J Med 2010; 363: Sureda A, et al. ASH Chen R, et al. ASH
14 Single agent activity of new agents in post SCT relapsed chl Comparison to multiagent chemotherapy GVD GVD SGN35 Everolimus SGN35 Panobinostat SGN35 MGCD0103 Panobinostat Lenalidomide Lenalidomide MDX060 Vorinostat SGN30 PR CR % Response rate Event-free survival for transplant-naive patients receiving gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), plus autologous stem-cell transplant in 39 of 49 (solid line), and patients receiving GVD after failing a prior transplant (dashed line). Bartlett N et al. Ann Oncol 2007;18: European Society for Medical Oncology 14
15 Event-free and overall survival of patients with chemosensitive disease.kaplan-meier estimates of the proportion of patients with chemosensitive disease to 2 cycles of ICE cytoreduction who are alive (+) and event free ( ) at a median follow-up of 43 months. Moskowitz C H et al. Blood 2001;97: by American Society of Hematology Results of salvage pre-transplant regimens in chl IGEV mini-beam ASHAP MINE Dexa-BEAM ICE CR PR DHAP GVD GDP ESHAP % response rate 15
16 Brentuximab Vedotin Mechanism of Action Brentuximab vedotin (SGN-35) ADC monomethyl auristatin E (MMAE), potent antimicrotubule agent protease-cleavable linker anti-cd30 monoclonal antibody ADC binds to CD30 ADC-CD30 complex traffics to lysosome MMAE is released MMAE disrupts microtubule network G2/M cell cycle arrest Apoptosis Phase I Brentuximab Vedotin in Relapsed HL Treatment Follow-up Cycle 1 21 days Cycle 2 21 days Restage* Stable disease or better may receive additional cycles D1 dosing D1 dosing SGN-35 administered IV every 21 days Dose cohorts: 0.1, 0.2, 0.4, 0.6, 0.8, 1.2, 1.8, 2.7, 3.6 mg/kg * CT and PET scans were retrospectively reviewed by an independent review facility (IRF) Younes A, et al. N Engl J Med 2010; 363:
17 Phase-I Brentuximab Vedotin in Relapsed HL Treatment Response Investigator Assessment IRF Assessment 86% of patients achieved tumor reductions 83% of patients achieved tumor reductions * Significant correlation observed between investigator and IRF assessment (Pearson correlation coefficient = 0.674; P<.001) Younes A, et al. N Engl J Med 2010; 363: Phase I Brentuximab Vedotin in Relapsed HL 21-year-old female HL diagnosed 2003 ABVD + XRT to mediastinum ICE BEAM ASCT HDAC-inhibitor SGN mg/kg x 8 cycles Best clinical response: CR CT 93% reduction, PET- PET negative Younes A, et al. N Engl J Med 2010; 363:
18 Durable Complete Remissions in a Pivotal Phase 2 Study of SGN-35 (Brentuximab Vedotin) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) A Younes, AK Gopal, SE Smith, SM Ansell, JD Rosenblatt, KJ Savage, JM Connors, A Engert, EK Larsen, DA Kennedy, EL Sievers, R Chen International Conference on Malignant Lymphoma June, 2011 Lugano, Switzerland Pivotal, Multicenter, Open-Label Study of Brentuximab Vedotin in Relapsed/Refractory HL Eligibility Treatment (N=102) Follow-up Relapsed or refractory CD30+ HL Age 12 years Measurable disease 1.5 cm ECOG 0 1 Prior ASCT Brentuximab vedotin 1.8 mg/kg IV every 21 days Administered outpatient over 30 min Max 16 cycles for SD or better Restage* at Cycles 2, 4, 7, 10, 13, 16 Every 12 weeks * Revised Response Criteria for Malignant Lymphoma (Cheson, 2007) 18
19 Demographics and Baseline Characteristics N=102 Age* (years) 31 (15 77) Gender (M / F) 48 / 54 ECOG status (0 / 1) 42 / 60 Refractory to frontline therapy 72 (71%) Refractory to most recent treatment 43 (42%) Prior chemotherapy regimens* 3.5 (1 13) Relapse 1 year post ASCT 72 (71%) Time from ASCT to first post transplant relapse* 6.7 mo (0 131) * Median (range) Response Results Summary N=102 Objective response (OR) rate 75% 95% CI 65, 83 Median duration of OR 6.7 mo 95% CI 3.6, 14.8 Median (range) cycles of treatment = 9 (1 16) Estimated 12-month overall survival = 89% 19
20 Tumo or Size (% Change from Baseline) Maximum Tumor Reduction Complete remission 94% (96 of 102) of patients achieved tumor reduction Individual Patients PFS by Best Response or Death % Patients Free of PD o Time (months) 20
21 HL: Opportumities to improve treatment outcome Front-line ABVD vs ABVD + SGN-35 Pretransplant (Salvage) vs (salvage) + X SGN-35 naive SGN-35 vs SGN-35 + X Post transplant Post SGN-35 New single agent vs control 21
Relapsed/Refractory Hodgkin Lymphoma
Relapsed/Refractory Hodgkin Lymphoma Anas Younes, MD Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center New York, New York, United States Case Study 32-year-old woman was diagnosed with stage
More informationBrentuximab Vedotin. Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center
Brentuximab Vedotin Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center U.S. Cancer Statistics 2016 300.000 249.260 224.390 200.000 180.890 Incidence 100.000 95.270 76.960
More informationChemotherapy-based approaches are the optimal second-line therapy prior to stem cell transplant in relapsed HL
Lymphoma & Myeloma 2015 Chemotherapy-based approaches are the optimal second-line therapy prior to stem cell transplant in relapsed HL Jeremy S. Abramson, MD Relevant Disclosure Consulting for Seattle
More informationGerman Hodgkin Study Group
German Hodgkin Study Group Deutsche Hodgkin Studiengruppe Avoiding Relapse of Hodgkin Lymphoma: Have We Moved The Needle? Andreas Engert, MD Chairman, German Hodgkin Study Group University Hospital of
More informationBrentuximab Vedotin in Lymphomas
New Drugs In Hematology Brentuximab Vedotin in Lymphomas Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center Monday, May 9, 2016 9:15-9:45 a.m U.S. Cancer Statistics 2016 300.000
More informationABVD versus BEACOPP arguments for ABVD. Dr Pauline BRICE Hôpital saint louis Université Paris VII PARIS
ABVD versus BEACOPP arguments for ABVD Dr Pauline BRICE Hôpital saint louis Université Paris VII PARIS DISCLOSURES HONORARIAS: Takeda, roche GRANT RESEARCH : Millenium Takeda, AMGEN ABVD the standard chemotherapy
More informationTreatment Approaches in Relapsed/Refractory HL. Brentuximab Vedo=n. Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Ke=ering Cancer Center
Treatment Approaches in Relapsed/Refractory HL Brentuximab Vedo=n Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Ke=ering Cancer Center Thursday March 15, 2018: 10:15-10:30 am 1992 (Cell): Durkop
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationDr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta
Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge ASH 2012 Atlanta DLBCL How to improve on R-CHOP What at relapse Mantle cell lymphoma Do we cure patients Treatment at relapse Follicular lymphoma Watch and
More informationConfronto Real world e studi registrativi
Confronto Real world e studi registrativi V. Pavone San Giovanni Rotondo 8 Novembre 2018 U.O Ematologia Az.Osp.Card.G.Panico MEDICAL NEED IN HL OUTCOME REDUCE TOXICITY IMPROVE FIRST LINE RISK-ADAPTED STRATEGY
More informationWhat is the best second-line approach to induce remission prior to stem cell transplant? Single agent brentuximab vedotin
What is the best second-line approach to induce remission prior to stem cell transplant? Single agent brentuximab vedotin Alison Moskowitz, MD Assistant Attending, Lymphoma Service Memorial Sloan Kettering
More informationWhat are the hurdles to using cell of origin in classification to treat DLBCL?
What are the hurdles to using cell of origin in classification to treat DLBCL? John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical
More informationKamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA
Kamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA Objectives Describe the current standard approach for patients with relapsed/refractory
More informationHodgkin Lymphoma. Barbara Pro, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Chicago, Illinois
Hodgkin Lymphoma Barbara Pro, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Chicago, Illinois Hodgkin Lymphoma Successes and Challenges The success 80 % of patients achieve
More informationLinfoma de Hodgkin. Novos medicamentos. Otavio Baiocchi CRM-SP
Linfoma de Hodgkin Novos medicamentos Otavio Baiocchi CRM-SP 96.074 Hodgkin Lymphoma Unique B-cell lymphoma HRS malignant cells Scattered malignant Hodgkin-Reed-Sternberg (RS) cells in a background of
More informationMantle Cell Lymphoma New scenario and concepts in front-line treatment for young pa:ents
Mantle Cell Lymphoma New scenario and concepts in front-line treatment for young pa:ents Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Ke=ering Cancer Center Friday March 16, 2018: 11:15-11:30
More informationThe treatment of DLBCL. Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona
The treatment of DLBCL Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona NHL frequency at the IOSI Mantle Cell Lymphoma 6.5 % Diffuse Large B-cell Lymphoma 37%
More informationThe Role of Stem Cell Transplantation in Relapsed / Refractory Hodgkin s Lymphoma
The Role of Stem Cell Transplantation in Relapsed / Refractory Hodgkin s Lymphoma Anna Sureda Haematology Department Institut Catala d Oncologia Hospital Duran I Reynals Barcelona, Spain 10 th Educational
More informationCAR-T cell therapy pros and cons
CAR-T cell therapy pros and cons Stephen J. Schuster, MD Professor of Medicine Perelman School of Medicine of the University of Pennsylvania Director, Lymphoma Program & Lymphoma Translational Research
More informationPET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma. Ranjana H. Advani, MD
PET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma Ranjana H. Advani, MD Stanford Cancer Institute Management of Hodgkin Lymphoma Learning Objectives Review risk adapted strategies
More informationAHSCT in Hodgkin lymphoma - indication and challenges. Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital
AHSCT in Hodgkin lymphoma - indication and challenges Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital AHSCT in Hodgkin Lymphoma The role of AHSCT in HL Mobilisation failure
More informationBendamustine for Hodgkin lymphoma. Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service
Bendamustine for Hodgkin lymphoma Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service Bendamustine in Hodgkin lymphoma Bifunctional molecule Nitrogen mustard component (meclorethamine)
More informationJonathan W Friedberg, MD, MMSc
I N T E R V I E W Jonathan W Friedberg, MD, MMSc Dr Friedberg is Professor of Medicine and Oncology and Chief of the Hematology/Oncology Division at the University of Rochester s James P Wilmot Cancer
More informationThe case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc.
The case against maintenance rituximab in Follicular lymphoma Jonathan W. Friedberg M.D., M.M.Sc. Follicular lymphoma: What are goals of treatment? Change natural history of disease: Decrease transformation
More informationAlexander Fosså, M.D. PhD.
Alexander Fosså, M.D. PhD. Current position: Senior Consultant, Department of Medical Oncology Oslo University Hospital Focus of work: - Malignant lymphoma - Chemotherapy, immunotherapy, radiotherapy -
More informationUpdates in the Treatment of Non-Hodgkin Lymphoma: ASH Topics
Updates in the Treatment of Non-Hodgkin Lymphoma: ASH 2008 Joseph Tuscano, M.D. UC Davis Cancer Center 1 Topics Mantle Cell Lymphoma What is the standard of care for younger patients? (abstracts 581, 769,
More informationPET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma
PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationThe Role of Stem Cell Transplantation in Relapsed / Refractory Hodgkin s Lymphoma
The Role of Stem Cell Transplantation in Relapsed / Refractory Hodgkin s Lymphoma Anna Sureda Haematology Department Hospital Universitari Quirón Dexeus Barcelona, Spain 9 th Educational Course on Lymphomas
More informationHodgkin Lymphoma Review of characteristics and treatment of elderly patients
Hodgkin Lymphoma Review of characteristics and treatment of elderly patients Boris Böll M.D. German Hodgkin Study Group (GHSG) University Hospital Cologne OS of HL patients in all stages 1960-1967 Courtesy
More informationWho should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University
Who should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University Treatment Challenges Several effective options, improve response durations, none curable
More informationRadiotherapy in DLCL is often worthwhile. Dr. Joachim Yahalom Memorial Sloan-Kettering, New York
Radiotherapy in DLCL is often worthwhile Dr. Joachim Yahalom Memorial Sloan-Kettering, New York The case for radiotherapy Past: Pre-Rituximab randomized trials Present: R-CHOP as backbone, retrospective
More informationLymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège. 14 th post-ash meeting, January 6 th 2011, Brussels
Lymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège 14 th post-ash meeting, January 6 th 2011, Brussels Hodgkin s lymphoma Follicular lymphoma Diffuse large B-cell lymphoma Mantle cell
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationAdvances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma
Wang et al. Journal of Hematology & Oncology (2018) 11:57 https://doi.org/10.1186/s13045-018-0601-9 REVIEW Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma Yucai Wang 1, Grzegorz
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationHodgkin Lymphoma New Combo-Steps
New Drugs In Hematology Hodgkin Lymphoma New Combo-Steps Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center Monday, May 9, 2016 2:55-3:10 p.m Combinations with Immune Checkpoint
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationPOST ICML Indolent lymphomas relapse treatment
POST ICML Indolent lymphomas relapse treatment Georg Hess University Medical School Johannes Gutenberg-University Mainz, Germany Treatment of relapsed indolent lymphoma 2 General categories of second line
More informationMANTLE CELL LYMPHOMA
MANTLE CELL LYMPHOMA CLINICAL CASE PRESENTATION Martin Dreyling Medizinische Klinik III LMU München Munich, Germany esmo.org Multicenter Evaluation of MCL Annency Criteria fulfilled event free interval
More informationNew Agents Beyond Brentuximab vedotin for Hodgkin Lymphoma. Stephen M. Ansell, MD, PhD Professor of Medicine Mayo Clinic
New Agents Beyond Brentuximab vedotin for Hodgkin Lymphoma Stephen M. Ansell, MD, PhD Professor of Medicine Mayo Clinic Disclosures for Stephen Ansell, MD, PhD In compliance with ACCME policy, Mayo Clinic
More informationRelapsed/Refractory Hodgkin Lymphoma
Relapsed/Refractory Hodgkin Lymphoma Robert Chen, MD Associate Professor of Medicine Co-Leader of Lymphoma Disease Team Associate Director of Toni Stephenson Lymphoma Center City of Hope National Medical
More informationToday, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center
Today, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center Today, how many PTCL patients are cured? Some but not as many
More informationMMAE disrupts cell division and triggers apoptosis. Pola binds to cell surface antigen CD79b. Pola is internalized; linker cleaves, releasing MMAE
Adding Polatuzumab Vedotin (Pola) to Bendamustine and Rituximab () Treatment Improves Survival in Patients With Relapsed/Refractory DLBCL: Results of a Phase II Clinical Trial Abstract S802 Sehn LH, Kamdar
More information12 th Annual Hematology & Breast Cancer Update Update in Lymphoma
12 th Annual Hematology & Breast Cancer Update Update in Lymphoma Craig Okada, MD, PhD Assistant Professor, Hematology January 14, 2010 Governors Hotel, Portland Oregon Initial Treatment of Indolent Lymphoma
More informationR/R DLBCL Treatment Landscape
An Updated Analysis of JULIET, a Global Pivotal Phase 2 Trial of Tisagenlecleucel in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Abstract S799 Borchmann P, Tam CS, Jäger U,
More informationDr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009
Treatment of DLBCL Dr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009 Non-hodgkin lymphomas DLBCL Most common NHL subtype throughout the world many other types of lymphoma with striking geographic variations
More informationAdvanced stage HL The old and new match: BEACOPP
27.03.2015 1 Advanced stage HL The old and new match: BEACOPP Peter Borchmann German Hodgkin Study Group University of Cologne, Germany Which answer is wrong? For patients with advanced stage HL, treatment
More informationBrentuximab Vedotin in CD30+ Lymphomas
Biol Ther (2013) 3:15 23 DOI 10.1007/s13554-013-0008-7 REVIEW Brentuximab Vedotin in CD30+ Lymphomas Guilherme Fleury Perini Barbara Pro To view enhanced content go to www.biologicstherapy-open.com Received:
More informationMantle cell lymphoma An update on management
Mantle cell lymphoma An update on management Dr Kim Linton Consultant Medical Oncologist The Christie NHS Foundation Trust 6 th October 2016 This educational meeting is organised and sponsored by Janssen-Cilag
More informationBrad S Kahl, MD. Tracks 1-21
I N T E R V I E W Brad S Kahl, MD Dr Kahl is Associate Professor and Director of the Lymphoma Service at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical
More informationNON-HODGKIN LYMPHOMA TREATMENT REGIMENS: Peripheral T-Cell Lymphoma (Part 1 of 5)
Peripheral T-Cell Lymphoma (Part 1 of 5) Clinical Trials: The National Comprehensive Cancer Network recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer
More informationDisclosures WOJCIECH JURCZAK
Disclosures WOJCIECH JURCZAK ABBVIE (RESEARCH FUNDING), CELGENE (RESEARCH FUNDING); EISAI (RESEARCH FUNDING); GILEAD (RESEARCH FUNDING); JANSEN (RESEARCH FUNDING); MORPHOSYS (RESEARCH FUNDING), MUNDIPHARMA
More informationNew Targets and Treatments for Follicular Lymphoma
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,
More informationUpdates in T cell Lymphoma
Winship Cancer Institute of Emory University Updates in T cell Lymphoma Mary Jo Lechowicz August 2014 Objectives Update current care for patients with Peripheral T cell Non Hodgkin lymphomas (PTCL) upfront
More informationDoes BV as part of salvage impact outcome?
Does BV as part of salvage impact outcome? Craig Moskowitz, MD Steven A. Greenberg Chair in Lymphoma Research Member, Memorial Sloan Kettering Cancer Center Professor of Medicine, Weill Medical College
More informationBleomycin versus Brentuximab in Hodgkin Lymphoma: Don t Hold Your Breath
Bleomycin versus Brentuximab in Hodgkin Lymphoma: Don t Hold Your Breath Rachel Bubik, PharmD, BCPS PGY-2 Hematology/Oncology Pharmacy Resident January 8 th, 2019 2017 MFMER slide-1 Objectives 1. Explain
More informationOpen questions in the treatment of Follicular Lymphoma. Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland
Open questions in the treatment of Follicular Lymphoma Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland Survival of major lymphoma subtypes at IOSI 1.00 cause-specific
More informationFirenze, settembre 2017 Novità dall EHA LINFOMI Umberto Vitolo
Firenze, 22-23 settembre 2017 Novità dall EHA LINFOMI Umberto Vitolo Hematology University Hospital Città della Salute e della Scienza Torino, Italy Disclosures Umberto Vitolo Research Support/P.I. Employee
More informationAggressive B and T cell lymphomas: Treatment paradigms in 2018
Aggressive B and T cell lymphomas: Treatment paradigms in 2018 John P. Leonard M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Associate
More informationRADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA
RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA Pier Luigi Zinzani Institute of Hematology and Medical Oncology L. e A. Seràgnoli University of Bologna, Italy Slovenia, October 5 2007 Zevalin
More informationChanging the landscape of treatment in Peripheral T-cell Lymphoma
Changing the landscape of treatment in Peripheral T-cell Lymphoma Luis Fayad Associate Professor MD Anderson Cancer Center Department of Lymphoma and Myeloma 1 6 What is peripheral 2008 WHO CLASSIFICATION
More informationPrognostic Value of Early Introduction of Second Line in Patients with Diffuse Large B Cell Lymphoma
Med. J. Cairo Univ., Vol. 84, No., December: 443-447, 6 www.medicaljournalofcairouniversity.net Prognostic Value of Early Introduction of Second Line in Patients with Diffuse Large B Cell Lymphoma HAMDY
More informationMantle Cell Lymphoma
Mantle Cell Lymphoma Clinical Case A 56 year-old woman complains of pain and fullness in the left superior abdominal quadrant for the last 8 months. She has lost 25 kg, and lately has had night sweats.
More informationMantle Cell Lymphoma: Update in Diego Villa, MD MPH FRCPC Medical Oncologist BC Cancer Agency
Mantle Cell Lymphoma: Update in 2015 Diego Villa, MD MPH FRCPC Medical Oncologist BC Cancer Agency Disclosures Research funding: Roche provides research funding to support the Centre for Lymphoid Cancer
More informationResponse Adapted treatment of chl using BV in first line. Massimo Federico University of Modena and Reggio Emilia Italy
Response Adapted treatment of chl using BV in first line Massimo Federico University of Modena and Reggio Emilia Italy From the book of 18FDG-PET in BV treatment patients 1 In the beginning Seattle Genetics
More informationPractical Application of PET adapted Therapy in Hodgkin Lymphoma
Practical Application of PET adapted Therapy in Hodgkin Lymphoma Matthew Matasar, MD Lymphoma and Adult BMT Services Director, Lymphoma Survivorship Clinic Memorial Sloan Kettering Cancer Center New York,
More informationPembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study
Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study Craig H. Moskowitz, 1 Pier Luigi Zinzani, 2 Michelle A. Fanale, 3 Philippe Armand, 4 Nathalie Johnson, 5 John
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationCARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre
CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS
More informationLymphoma. André Bosly M.D.,Ph.D. Post ASH meeting 10/01/2014 Sheraton Brussels National Airport
Lymphoma André Bosly M.D.,Ph.D. Post ASH meeting 10/01/2014 Sheraton Brussels National Airport Lymphoma Hodgkin Lymphoma (HL) Indolent Lymphoma (inhl) Diffuse Large B Cell Lymphoma (DLBCL) Hodgkin Lymphoma
More informationK. Lisenko 1*, F. McClanahan 2, T. Schöning 3, M. A. Schwarzbich 1, M. Cremer 1, T. Dittrich 1,A.D.Ho 1 and M. Witzens-Harig 1
Lisenko et al. BMC Cancer (2016) 16:267 DOI 10.1186/s12885-016-2289-y RESEARCH ARTICLE Open Access Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with
More informationDisclosures for Dr. Peter Borchmann 48 th ASH Annual meeting, Orlando, Florida
Phase II Study of Pixantrone in Combination with Cyclophosphamide, Vincristine, and Prednisone (CPOP) in Patients with Relapsed Aggressive Non-Hodgkin s Lymphoma P Borchmann Universitaet de Koeln, Koeln,
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationRituximab in the Treatment of NHL:
New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance Therapy in FL with Standard or Rapid Infusion,
More informationDiffuse Large B-Cell Lymphoma Front line Therapy John P. Leonard, MD Weill Cornell Medicine New York, New York USA
Diffuse Large B-Cell Lymphoma Front line Therapy John P. Leonard, MD Weill Cornell Medicine New York, New York USA Disclosures Consulting advice: Hospira, Bayer, Juno Therapeutics, Teva, Oncotracker, Gilead
More informationTargeted Radioimmunotherapy for Lymphoma
Targeted Radioimmunotherapy for Lymphoma John Pagel, MD, PhD Fred Hutchinson Cancer Center Erik Mittra, MD, PhD Stanford Medical Center Brought to you by: Financial Disclosures Disclosures Erik Mittra,
More informationHave we moved beyond EPOCH for B-cell non-hodgkin lymphoma? YES!
Have we moved beyond EPOCH for B-cell non-hodgkin lymphoma? YES! Christopher Flowers, MD, MSc Associate Professor Director, Lymphoma Program Department of Hematology and Oncology Emory School of Medicine
More informationPublished Ahead of Print on April 2, 2009 as /theoncologist Salvage Therapy in Hodgkin s Lymphoma
The Oncologist Lymphoma Salvage Therapy in Hodgkin s Lymphoma JASON H. MENDLER,JONATHAN W. FRIEDBERG James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, USA Key
More informationManaging patients with relapsed follicular lymphoma. Case
Managing patients with relapsed follicular lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Professor of Medicine Associate Director, Weill Cornell
More informationHODGKIN LYMPHOMA Updated February 2016 by Dr. Manna (PGY 5 Hematology Resident, University of Calgary)
HODGKIN LYMPHOMA Updated February 2016 by Dr. Manna (PGY 5 Hematology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff
More informationWhat is the best approach to the initial therapy of PTCL? standards of treatment? Should all
What is the best approach to the initial therapy of PTCL? standards of treatment? hould all Jia Ruan, M.D., Ph.D. Center for Lymphoma and Myeloma Weill Cornell Medical College New York Presbyterian Hospital
More informationAggressive lymphomas ASH Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV
Aggressive lymphomas ASH 2015 Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV CHOP 1992 2002 R-CHOP For DLBCL High dose chemo With PBSCT Aggressive lymphomas 1.DLBCL 2.Primary Mediastinal Lymphoma 3.CNS
More informationbrentuximab vedotin (Adcetris ) 50mg powder for concentrate for solution for infusion SMC No. (845/12) Takeda UK Ltd
brentuximab vedotin (Adcetris ) 50mg powder for concentrate for solution for infusion SMC No. (845/12) Takeda UK Ltd 05 September 2014 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationAggressive NHL and Hodgkin Lymphoma. Dr. Carolyn Faught November 10, 2017
Aggressive NHL and Hodgkin Lymphoma Dr. Carolyn Faught November 10, 2017 What does aggressive mean? Shorter duration of symptoms Generally need treatment at time of diagnosis Immediate, few days, few weeks
More informationMantle Cell Lymphoma. A schizophrenic disease
23 maggio, 2018 Mantle Cell Lymphoma A schizophrenic disease Patients relapsed after Auto transplant EBMT registry 2000-2009 (n=360) 19 months OS 24 months OS Dietrich S, Ann Oncol 2014 Patients receiving
More informationBrentuximab, Nivolumab: L esperienza Real Word della REP. Dr.ssa Clara De Risi Az. Osp. Card. G. Panico - Tricase
Brentuximab, Nivolumab: L esperienza Real Word della REP Dr.ssa Clara De Risi Az. Osp. Card. G. Panico - Tricase MEDICAL NEED IN HL OUTCOME REDUCE TOXICITY IMPROVE FIRST LINE RISK-ADAPTED STRATEGY IMPROVE
More informationFirst Line Management of Classical Hodgkin Lymphoma
First Line Management of Classical Hodgkin Lymphoma George Follows Cambridge University Hospitals NHS Foundation Trust george.follows@addenbrookes.nhs.uk The controversial areas Early stage non-bulky /
More informationHow to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma
How to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma Dr. Guillermo Rodríguez García Hospital Universitario Virgen Macarena Hospital Universitario Virgen del
More informationBrentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas Anas Younes, M.D., Nancy L. Bartlett, M.D., John P. Leonard, M.D.,
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationAkiko Fukunaga, Mizuki Hyuga, Makoto Iwasaki, Yoshiki Nakae, Wataru Kishimoto, Yoshitomo Maesako, and Nobuyoshi Arima. Original Article INTRODUCTION
J Clin Exp Hematop Vol. 56, No. 1, June 216 Original Article Dose-Modified Ifosfamide, Epirubicin, and Etoposide is a Safe and Effective Salvage Therapy with High Peripheral Blood Stem Cell Mobilization
More informationHodgkin Lymphoma Nivolumab
New Drugs In Hematology Hodgkin Lymphoma Nivolumab Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center Monday, May 9, 2016 2:10-2:25 p.m immunotherapy modalities CAR T Cells
More informationInterim PET in Diffuse Large B Cell Lymphoma.The GEL/TAMO experience
Interim PET in Diffuse Large B Cell Lymphoma.The GEL/TAMO experience MD. Caballero, Hospital Universitario, Salamanca, Spain. Chair of The GEL/TAMO Group Menton,9 april 2010 Disclosures for Dolores Caballero
More informationTransplantation for Lymphoma What is New? Siddhartha Ganguly, MD, FACP
Transplantation for Lymphoma What is New? Siddhartha Ganguly, MD, FACP Professor of Medicine Director, Lymphoma/Myeloma Program Division of Hematologic Malignancies and Cellular Therapeutics University
More informationRelapse After Transplant: Next Steps for Patients with Hodgkin Lymphoma
Hi! My name is Alison Moskowitz. I am an attending at Memorial Sloan Kettering Cancer Center within the Lymphoma Department. I am speaking on behalf of ManagingHodgkinLymphoma.com. I will be discussing
More informationTreatment Landscape in R/R DLBCL Novel Targets and Strategies. Wyndham H. Wilson, M.D., Ph.D. Senior Investigator
Treatment Landscape in R/R DLBCL Novel Targets and Strategies Wyndham H. Wilson, M.D., Ph.D. Senior Investigator Gene-expression profiling of DLBCL subtypes Roschewski, M. et al. (2013) Nat. Rev. Clin.
More informationConflict of Interest Disclosure Form NAME :James O. Armitage, M.D AFFILIATION: University of Nebraska Medical Center
What Is Personalized Medicine For Patients With Lymphoma? Conflict of Interest Disclosure Form NAME :James O. Armitage, M.D AFFILIATION: University of Nebraska Medical Center DISCLOSURE I have no potential
More informationInotuzumab Ozogamicin in ALL. Hagop Kantarjian M.D. May 2016 Bologna, Italy
Inotuzumab Ozogamicin in ALL Hagop Kantarjian M.D. May 2016 Bologna, Italy Immuno Oncology in ALL Monoclonals + cytotoxic agents e.g.inotuzumab Bispecific monoclonals (CD3 + CD19) e.g.blinatumomab Modified
More informationWelcome and Introductions
Update on Hodgkin Lymphoma Matthew J Matasar, MD, MS Physician, Lymphoma and Adult BMT Services Director, Lymphoma Survivorship Clinic Memorial Sloan Kettering Cancer Center New York, NY April 1, 2016
More informationNCCN Non Hodgkin s Lymphomas Guidelines V Update Meeting 06/14/12 and 06/15/12
NCCN Non Hodgkin s Lymphomas Guidelines V.1.213 Update Meeting 6/14/12 and 6/15/12 Guidelines Page and Request Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL) Panel Discussion References
More information